TQ-B3234
Phase 3Small molecule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.TQ-B3234 is one of 4 small molecule programs targeting Plexiform Neurofibroma. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Plexiform Neurofibroma
#DrugCompanyPhaseTrials
1Koselugo
AstraZenecaPhase 3
Mekinist
NovartisPhase 2
TQ-B3234
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Mirdametinib and Carbamazepine
SSpringWorks Therapeutics, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Plexiform Neurofibroma1 trial
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
Not yet recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT07407803·177 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT07407803·177 enrolledNeurofibromatosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TQ-B3234. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details